Ilika Trading Update and Notice of Results

AI SummaryClose X

Ilika plc announced its full-year trading update for the period ending 30 April 2026, expecting revenues of approximately £1.1 million, including £100,000 from Stereax electrode sales, and an EBITDA loss of around £6.2 million, an increase from the previous year's £5.2 million loss. The company's cash reserves stood at £5.3 million, down from £8.0 million. Significant progress was made with the Stereax product line, securing its first revenue-generating purchase order from Cirtec Medical for electrodes, and the Goliath product line received automotive customer validation, secured £1.25 million in grant funding for A-Samples, commissioned an automated assembly line for 10Ah cells, and received positive feedback from a UK defence agency, alongside initiating a joint development programme with Brompton for e-bikes.

Disclaimer*

Companies

Ilika (IKA)
UK 100

Latest directors dealings